The A4GALT locus encodes a glycosyltransferase that synthesizes the terminal Gal␣1-4Gal of the P k (Gb3/CD77) glycosphingolipid, important in transfusion medicine, obstetrics, and pathogen susceptibility. Critical nucleotide changes in A4GALT not only abolish P k formation but also another Gal␣1-4Gal-defined antigen, P1, which belongs to the only blood group system for which the responsible locus remains undefined. Since known A4GALT polymorphisms do not explain the P1؊P k ؉ phenotype, P 2 , we set out to elucidate the genetic basis of P 1 /P 2 . Despite marked differences (P 1 > P 2 ) in A4GALT transcript levels in blood, luciferase experiments showed no difference between P 1 /P 2 -related promoter sequences. Investigation of A4GALT mRNA in cultured human bone marrow cells revealed novel transcripts containing only the noncoding exon 1 and a sequence (here termed exon 2a) from intron 1. These 5-capped transcripts include poly-A tails and 3 polymorphic sites, one of which was P 1 /P 2 -specific among > 200 donors and opens a short reading frame in P 2 alleles. We exploited these data to devise the first genotyping assays to predict P1 status. P 1 /P 2 genotypes correlated with both transcript levels and P1/P k expression on red cells. Thus, P 1 zygosity partially explains the well-known interindividual variation in P1 strength. Future investigations need to focus on regulatory mechanisms underlying P1 synthesis. (Blood. 2011; 117(2):678-687)